High‐throughput, non‐invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti‐D immunoglobulin: a cost‐effectiveness analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  BJOG: an International Journal of Obstetrics and Gynaecology

• Publication date

  2018-10-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1111/1471-0528.15152PMID 29415334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.

  2018cited by this paper
• Cost‐effectiveness of first trimester non‐invasive fetal RHD screening for targeted antenatal anti‐D prophylaxis in RhD‐negative pregnant women: a model‐based analysis

  2016cited by this paper
• National Institute for Health and Care Excellence.

  2015cited by this paper
• Costs and benefits of non‐invasive fetal RhD determination

  2015cited by this paper
• Use of cffDNA to avoid administration of anti‐D to pregnant women when the fetus is RhD‐negative: implementation in the NHS

  2015cited by this paper
• Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study

  2014cited by this paper
• Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice

  2014cited by this paper
• Costs and Clinical Outcomes of Noninvasive Fetal RhD Typing for Targeted Prophylaxis

  2013cited by this paper
• Cost-effectiveness of the management of rh-negative pregnant women.

  2013cited by this paper
• A new fetal RHD genotyping test: Costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales

  2011cited by this paper
• Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.

  2009cited by this paper
• Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.

  2009cited by this paper
• Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study

  2008cited by this paper
• Decision modelling for health economic evaluation

  2007cited by this paper
• Routine antenatal anti‐D prophylaxis and patient compliance with the two‐dose regimen

  2007cited by this paper
• The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype.

  2000cited by this paper
• Molecular background of VS and weak C expression in blacks

  1997cited by this paper
• Anti-D administration after childbirth for preventing Rhesus alloimmunisation.

  1997cited by this paper

• Genotipificación fetal RHD no invasiva en plasma materno: hacia una mejor atención materna e infantil en Uruguay

  2026cites this paper
• A Narrative Review: Maternal Comorbidities and Amniocentesis-Related Complications

  2026cites this paper
• Is fetal RHD genotyping without fetal markers still unacceptable in D-alloimmunized RhD negative pregnant women?

  2025cites this paper
• Antenatal RHD screening to guide antenatal anti-D immunoprophylaxis in non-immunized D– pregnant women

  2024cites this paper
• Internationale richtlijnen voor het gebruik van Rhesus D immunoglobuline: een vergelijkend onderzoek en de plaats van foetale Rhesus D genotypering

  2023cites this paper
• Validation of a Non-invasive Prenatal Test for Fetal RhD, C, c, E, Kell and FyA Antigens.

  2023cites this paper
• Validation of a non-invasive prenatal test for fetal RhD, C, c, E, K and Fya antigens

  2023cites this paper
• Early translation of biochemical, metabolic, and genetic discoveries into clinical medicine

  2022cites this paper
• A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC)

  2022cites this paper
• Cost‐effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies

  2022cites this paper
• Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.

  2021cites this paper
• Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.

  2020cites this paper
• Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria

  2019cites this paper
• Pleura and Peritoneum

  2017cites this paper